Company Overview

Update
Founded:
1989
Headquarters:
Cambridge, MA
IPO:
Went Public on Jan 14, 2000
Stock:
NASDAQ:IDRA
Categories:
Biotechnology

Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.

Description

Update

Idera Pharmaceuticals, Inc., a biotechnology company, discovers and develops DNA- and RNA-based drug candidates for the treatment of infectious diseases, autoimmune and inflammatory diseases, cancer, and asthma and allergies, and for use as vaccine adjuvants. The company designs and creates proprietary Toll-Like Receptors (TLR) to modulate immune responses, including TLR agonist, a compound that stimulates an immune response through the targeted TLR; and TLR antagonist, a compound that blocks activation of an immune response through the targeted TLR. Its drug candidates include IMO-2125, a TLR9 agonist, which is in Phase 1 clinical trial for hepatitis C virus infection; and TLR7, 8, and 9 agonists that are in research stage for viral diseases. The company also develops IMO-3100, a dual TLR7/TLR9 antagonist, which is in preclinical development stage for autoimmune and inflammatory diseases, such as lupus, rheumatoid arthritis,... See More

Current Team (6)

Update

Board Members and Advisors (14)

Update

Funding Rounds (3) - $53.80M

Update

Investors (1)

Update
  • B3fd546222f7b694b4da812edacb444a

    Merck KGaA

    Merck KGaA is a pharmaceutical and chemical enterprise that develops prescription drugs and..

Offices/Locations (1)

Update
  • Office

    167 Sidney Street

    Cambridge, MA 02139

    USA

Images (1)

Update
  • Eca59bc0511728faf0037ee197c2b581